Where do we start?
Our initial focus will be on the provision of compassionate treatment for terminally-ill Canadians who suffer from end-of-life distress. End-of-life distress is best described as the combination of anxiety, depression, hopelessness, and demoralization experienced by patients who receive a diagnosis of a terminal illness from diseases such as cancer, HIV/AIDS, or heart disease. As research in psychedelic medicine matures, we will further expand our services to include others who may benefit from psilocybin.
“At the 6-month follow-up mark, 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety”
– Griffiths et a.l 2016
Unfortunately, current access to psychedelic-assisted psychotherapy is almost non-existent and remains illegal in Canada. In addition, we do not anticipate these medicines being made available to Canadians in the foreseeable future. At the current rate of progress, it may be years before psilocybin completes Phase 3 clinical trials and becomes available as a legitimate Health Canada approved medical option. In the meantime, many Canadians are suffering severely from end-of-life distress, and are in dire need of relief now.